It is noteworthy, however, that Mora and colleagues reported particularly good and favorable survival outcomes with the combined administration of Naxitamab, a GD2 antibody, and GM-CSF without PD-L1 blockade in a recently published phase II clinical trial involving 76 neuroblastoma patients. The gene discussed is CSF2; the disease is neuroblastoma.